About Synageva
Synageva is a company based in Lexington (United States) founded in 1996 by Sanj K Patel was acquired by Alexion in May 2015. Synageva has raised $127.64 million across 10 funding rounds from investors including Alexion, New Leaf Venture Partners and NIST. Synageva has completed 1 acquisition, including Trimeris. Synageva offers products and services including Handphone, Laptop, Fashion Items, and Beauty Products. Synageva operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Lexington, United States
- Founders Sanj K Patel
- SectorsHealthcare
- Email••••••••
- Website synageva.com
- Social LinkedIn YouTube
- Acquired by Alexion (May 2015)
Products & Services of Synageva
Synageva offers a comprehensive portfolio of products and services, including Handphone, Laptop, Fashion Items, and Beauty Products.
Mobile devices for communication and daily use
Computers for work, gaming, and entertainment
Clothing and accessories for men, women, and kids
Items for skincare, makeup, and personal care
Apps and channels of Synageva
its YouTube channel Lazada Indonesia has 13.5K subscribers and 30 videos.
Videos from Synageva
The most watched videos on Synageva's YouTube channel, Lazada Indonesia (13.5K subscribers). Click a video to play it here.
More on Lazada Indonesia.
Funding Insights of Synageva
Synageva has successfully raised a total of $127.64M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $25 million completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.64M
- Total Rounds 10
- Last Round Series D — $25M
- First Round $1.5M
(Jun 1998)
- Investors Count 7
All 10 funding rounds of Synageva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2011 | $25M | Series D | – | – | |
| Jul 2010 | $45M | Series C | – | Tullis Health Investors | – |
| Oct 2009 | $12M | Series C | – | – | |
| Feb 2009 | $6.62M | Series B | – | – | – |
| Oct 2007 | $10.13M | Series B | – | – | – |
| Aug 2005 | $14M | Series A | – | – | – |
| Mar 2005 | $4.88M | Series A | – | – | – |
| Oct 2000 | $10M | Series A | – | – | |
| Oct 2000 | $2M | Grant | – | – | |
| Jun 1998 | $1.5M | Grant | – | – |
8 investors in total: 8 institutional.
Investors in Synageva
Synageva has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, New Leaf Venture Partners and NIST.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
- | – | yedvc.co.jp | - | |
Private equity firm focused on multiple sectors | – | stephensgroup.com | Little Rock, United States | |
Investments are directed toward young firms in pharmaceuticals and biotech. | – | huntbioventures.com | Dallas, United States | |
Healthcare investments are made by Tullis Health Investors. | – | tullisfunds.com | Palm Beach Gardens, United States | |
- | – | cordovaventures.com | - | |
Standards and measurements are developed by NIST for various industries. | 1901 | nist.gov | United States | |
Therapies for rare and devastating diseases are developed by Alexion. | 1992 | alexion.com | Zurich, Switzerland |
Investor details for Synageva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synageva
1 people are tracked at Synageva (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sanj K Patel | Founder & CEO | Leadership |
Complete people profiles for Synageva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synageva
Synageva has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Trimeris.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Fusion inhibitor drugs for viral infections were developed. | trimeris.com | Durham, United States | 1993 | Jun 2011 | •••• |
Complete acquisition details for Synageva
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Synageva
Competitors of Synageva
Synageva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| sanofigenzyme.com | 1981 | Cambridge, United States | – | – | Antibody-drug conjugates are developed for treating multiple diseases. | |
| amicusrx.com | 2002 | Philadelphia, United States | $91M | 517 | Developer of therapies for rare and orphan diseases |
Detailed competitors of Synageva
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synageva
Complete news archive for Synageva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Synageva
10 companies that operate in the same segment as Synageva (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Synageva
Synageva was founded in 1996 and raised its 1st funding round 2 years after it was founded.
Synageva is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Sanj K Patel is the current CEO of Synageva. They have also founded this company.
Synageva is a funded company, having raised a total of $127.64M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.5M, raised on Jun 1998.
Founded in 1996, Synageva is based in Lexington, United States, where focus is placed on the biotechnology sector for rare diseases. Enzyme replacement therapies such as SBC-102 for LAL deficiency and SBC-103 for mucopolysaccharidosis IIIB deficiency are advanced. Additional protein therapeutics targeting life-threatening conditions are included in the pipeline, with operations centered on therapeutic development for unmet medical needs.
Synageva's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Synageva offers Handphone, Laptop, Fashion Items, and Beauty Products.
Synageva has made 1 acquisition, including Trimeris.
Synageva has 8 investors. Key investors include Alexion, New Leaf Venture Partners, NIST, Yasuda Enterprise Development, and The Stephens Group.
Yes. Synageva was acquired by Alexion in May 2015.